The association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer

Chenxue Jiang, Yanling Guo, Yefei Li, Jingjing Kang, Xiaojiang Sun, Hongyu Wu, Jianguo Feng, Yaping Xu, Chenxue Jiang, Yanling Guo, Yefei Li, Jingjing Kang, Xiaojiang Sun, Hongyu Wu, Jianguo Feng, Yaping Xu

Abstract

Background: This study sought to investigate the association between the ERCC1/2 single-nucleotide polymorphisms (SNPs) and the efficacy of radiotherapy and prognosis in patients with non-small cell lung cancer (NSCLC).

Methods: We examined 6 SNPs in the ERCC1 and ERCC2 genes in 87 consecutive patients with NSCLC who were treated with definitive radiotherapy. The objective remission rates (ORR), overall survival (OS), and progressive-free survival (PFS) were assessed. A Cox regression analysis was conducted to analyze the independent factors related to death and recurrence.

Result: Patients with the G allele had better OS than patients with the A allele, and there was a statistical difference between the two groups (30.9 vs. 16.2 months; P=0.003). Patients with the AA genotype had significantly worse OS than patients with the AG or GG genotypes (6.8 vs. 19.8 vs. 30.9 months, respectively; P=0.000). The median PFS of the G allele was 18.9 months, which was significantly better than that of the A allele (P=0.040). The median PFS of patients with the GG genotype, the AG genotype, and the AA genotype was 18.9, 11.3, and 5.1 months, respectively; the difference among the three groups was statistically significant (P=0.019). Patients with the G allele also had better PFS than those with the A allele (18.9 vs. 11.3 months, P=0.040). The multivariate cox proportional hazard analysis showed that the ERCC1 gene rs11615 was an independent survival indicator [HR: 1.623, 95% confidence interval (CI): 1.018-2.591, P=0.042] but not an independent recurrence indicator (HR: 1.497, 95% CI: 0.932-2.404, P=0.095).

Conclusions: The ERCC1 rs11615 SNP may be a potential biomarker for predicting survival prognosis in Chinese NSCLC patients who have undergone definitive radiotherapy. Patients with the G allele had better OS than those with the A allele.

Keywords: Non-small cell lung cancer (NSCLC); radiotherapy; single-nucleotide polymorphisms (SNPs).

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-21-755). The authors have no conflicts of interest to declare.

2021 Journal of Thoracic Disease. All rights reserved.

Figures

Figure 1
Figure 1
Kaplan-Meier curves of OS of the ERCC1 gene rs11615 SNP in 87 NSCLC patients who received definitive radiotherapy. (A) OS at allele gene level (P=0.003); (B) OS at genotype level (P=0.000). OS, overall survival; SNP, single-nucleotide polymorphism; NSCLC, non-small cell lung cancer.
Figure 2
Figure 2
Kaplan-Meier curves of PFS of the ERCC1 gene rs11615 SNP in NSCLC 87 patients who received definitive radiotherapy. (A) PFS at allele gene level (P=0.040); (B) PFS at genotype level (P=0.019). PFS, progressive-free survival; SNP, single-nucleotide polymorphism; NSCLC, non-small cell lung cancer.

References

    1. Avinash Tejasvi ML, Maragathavalli G, Putcha UK, et al. Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. Indian J Pathol Microbiol 2020;63:538. 10.4103/IJPM.IJPM_964_19
    1. Gillet LC, Schärer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev 2006;106:253-76. 10.1021/cr040483f
    1. Liao WY, Ho CC, Tsai TH, et al. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. Lung Cancer 2018;118:90-6. 10.1016/j.lungcan.2018.01.011
    1. Grenda A, Błach J, Szczyrek M, et al. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non‐small cell lung cancer patients. Cancer Med 2020;9:605-14. 10.1002/cam4.2743
    1. Bushra MU, Rivu SF, Sifat AE, et al. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh. Mol Biol Rep 2020;47:7073-82. 10.1007/s11033-020-05771-2
    1. Anoushirvani AA, Aghabozorgi R, Ahmadi A, et al. The relationship between rs3212986C> a polymorphism and tumor stage in lung cancer patients. Cureus 2019;11:e4423. 10.7759/cureus.4423
    1. Pérez-Ramírez C, Cañadas-Garre M, Alnatsha A, et al. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics J 2019;19:164-77. 10.1038/s41397-018-0014-8
    1. Zhang L, Yang M, Bi N, et al. Association of TGF-β1 and XPD polymorphisms with severe acute radiation-induced esophageal toxicity in locally advanced lung cancer patients treated with radiotherapy. Radiother Oncol 2010;97:19-25. 10.1016/j.radonc.2010.08.015
    1. Gillet LC, Schärer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev 2006;106:253-76. 10.1021/cr040483f
    1. Yang Y, Xian L. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol 2014;35:2905-21. 10.1007/s13277-013-1493-5
    1. Tan LM, Qiu CF, Zhu T, et al. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis. Sci Rep 2017;7:5593. 10.1038/s41598-017-05642-0
    1. Ren S, Zhou S, Wu F, et al. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer 2012;75:102-9. 10.1016/j.lungcan.2011.05.023
    1. Li F, Xie X, Ren X, et al. A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy. Cancer Chemother Pharmacol 2016;77:1183-91. 10.1007/s00280-016-3015-9
    1. Sullivan I, Salazar J, Majem M, et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett 2014;353:160-6. 10.1016/j.canlet.2014.07.023
    1. Huang X, Liu C, Cui Y, et al. Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett 2017;13:704-14. 10.3892/ol.2016.5496
    1. Zhao L, He X, Shang Y, et al. Identification of potential radiation-responsive biomarkers based on human orthologous genes with possible roles in DNA repair pathways by comparison between Arabidopsis thaliana and homo sapiens. Sci Total Environ 2020;702:135076. 10.1016/j.scitotenv.2019.135076
    1. Jin JY, Wang W, Ten Haken RK, et al. Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation dose-response in patients with non-small cell lung cancer. Radiother Oncol 2015;117:77-82. 10.1016/j.radonc.2015.07.024
    1. Du L, Yu W, Dai X, et al. Association of DNA repair gene polymorphisms with the risk of radiation pneumonitis in lung cancer patients. Oncotarget 2017;9:958. 10.18632/oncotarget.22982
    1. Zhang L, Yang M, Bi N, et al. ATM polymorphisms are associated with risk of radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 2010;77:1360-8. 10.1016/j.ijrobp.2009.07.1675
    1. Aiello MM, Solinas C, Santoni M, et al. Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer. Front Oncol 2020;10:1167. 10.3389/fonc.2020.01167

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere